Who makes CsA+ATG+Herombopag?

CsA+ATG+Herombopag is developed by Peking Union Medical College Hospital.

What development phase is CsA+ATG+Herombopag in?

CsA+ATG+Herombopag is FDA-approved (marketed).

What are the side effects of CsA+ATG+Herombopag?

Common side effects include Infection, Hemorrhage, Renal toxicity, Hepatotoxicity, Serum sickness (ATG-related), Thrombosis (eltrombopag-related).

Last reviewed 2026-04-22 · How we verify

CsA+ATG+Herombopag

Peking Union Medical College Hospital · FDA-approved active Small molecule

This combination therapy suppresses the immune system while promoting platelet production to treat aplastic anemia.

This combination therapy suppresses the immune system while promoting platelet production to treat aplastic anemia. Used for Aplastic anemia (immunosuppressive therapy-naïve or relapsed/refractory).

At a glance

Generic name	CsA+ATG+Herombopag
Also known as	SAA group intervention treatment
Sponsor	Peking Union Medical College Hospital
Drug class	Immunosuppressive agent + thrombopoietin receptor agonist combination
Target	Calcineurin (CsA); T lymphocytes (ATG); thrombopoietin receptor (eltrombopag)
Modality	Small molecule
Therapeutic area	Hematology/Immunology
Phase	FDA-approved

Mechanism of action

Cyclosporine A (CsA) is a calcineurin inhibitor that suppresses T-cell mediated immune responses, while anti-thymocyte globulin (ATG) provides additional immunosuppression by depleting T lymphocytes. Eltrombopag (Herombopag) is a thrombopoietin receptor agonist that stimulates megakaryocyte development and platelet production. Together, they address both the immune-mediated bone marrow failure and thrombocytopenia characteristic of aplastic anemia.

Approved indications

Aplastic anemia (immunosuppressive therapy-naïve or relapsed/refractory)

Common side effects

Infection
Hemorrhage
Renal toxicity
Hepatotoxicity
Serum sickness (ATG-related)
Thrombosis (eltrombopag-related)

Key clinical trials

Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CsA+ATG+Herombopag CI brief — competitive landscape report
CsA+ATG+Herombopag updates RSS · CI watch RSS
Peking Union Medical College Hospital portfolio CI